- Home
- FENC vs EIKN Comparison
FENC vs EIKN Comparison
Compare FENC & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | EIKN |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | 35 | 384 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.0M | 401.9M |
| IPO Year | 2010 | 2026 |
Fundamental Metrics
Financial Performance| Metric | FENC | EIKN |
|---|---|---|
| Price | $9.98 | $7.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $17.67 | ★ $24.60 |
| AVG Volume (30 Days) | 115.9K | ★ 569.9K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $62.55 | N/A |
| Revenue Next Year | $42.10 | N/A |
| P/E Ratio | $172.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $6.45 |
| 52 Week High | $13.25 | $16.50 |
Technical Indicators
Market Signals| Indicator | FENC | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 40.31 |
| Support Level | $9.87 | $7.02 |
| Resistance Level | $10.66 | $10.20 |
| Average True Range (ATR) | 0.49 | 0.52 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 12.90 | 54.96 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About EIKN Eikon Therapeutics Inc. Common Stock
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.